Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

OKYO Pharma Limited: Another Ophthalmology Firm with Promising Eye Treatment

January 11, 2024 0

Improving eyesight is speeding towards treating devastating eye diseases from the Retina in the back of …

Vertex Pharmaceuticals Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 9, 2024 0

Vertex Pharmaceuticals Updates Vertex Pharmaceuticals (VRTX) announced multiple program updates ahead of the upcoming investor meetings …

Cognition Therapeutics CEO Issues Letter to Shareholders

January 4, 2024 0

Cognition Therapeutics CEO Letter to Shareholders Cognition Therapeutics (CGTX) today announced that CEO Lisa Ricciardi has …

CymaBay Therapeutics: New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

January 3, 2024 0

CymaBay Therapeutics in the NEWS CymaBay Therapeutics (CBAY) today announced the first published findings demonstrating the …

Yes, Compugen’s Stock is Soaring, But Why?

January 2, 2024 0

Compugen's Soaring Stock Many recent events led to Compugen's (CGEN) soaring stock after a huge decline …

Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

December 29, 2023 0

Cytokinetics We recently became enthusiastic about Cytokinetics’ (CYTK) current clinical trial results. A few days ago, …

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label

December 28, 2023 0

Sarepta Therapeutics in the NEWS On 12, 22, 2023, Sarepta Therapeutics (SRPT) - a precision genetic …

Why Arcturus Therapeutics Holdings’ Pipeline Products are Promising

December 27, 2023 0

The information is the first of a few biotech Companies that we believe are promising in …

Immunovent, Altimmune and Soleno: A Summary of Three Firms We Believe Have Promising Technologies and Treatments

December 27, 2023 0

Immunovent, Altimmune & Soleno In addition to Vertex (VRTX), Crispr Therapeutics (

Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

December 20, 2023 0

Anavex Life Sciences Promising News From Anavex Life Sciences (AVXL) we learned that The Committee for Medicinal Products …

Merck & Invivyd in Today’s December 18, 2023 News

December 18, 2023 0

Merck & Invivyd in the NEWS Our post today comprises a premarket drug rejection. An important …

Prohost Letter #458 ~ Obesity

December 18, 2023 0

Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity …

Editas Medicine and Vertex Pharmaceuticals: Non-Exclusive License Agreement in Cas9 Gene Editing Technology

December 13, 2023 0

Editas Medicine and Vertex Pharmaceuticals in the NEWA Today December 13, 2023, Editas Medicine (EDIT) announced …

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

December 13, 2023 0

Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex Pharmaceuticals (VRTX) announced positive results from …

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

December 11, 2023 0

Crispr Therapeutics and Vertex Pharmaceuticals Gene Editing Therapey Will Be Marketed On Nov. 16, 2023, Crispr …

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

December 6, 2023 0

Novartis Approval Novartis (NVS) product Fabhalta (iptacopan) is a Factor B inhibitor that acts in the …

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

December 5, 2023 0

Roche in the NEWS From Basel, today, December 5, 2023 - Roche (RHHBY) announced positive results …

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

December 4, 2023 0

EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release, EyePoint Pharmaceuticals (EYPT) announced positive …

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

December 2, 2023 0

Altimmune Positive Topline Results Altimmune (ALT) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity …

AbbVie Inc to Acquire ImmunoGen

November 30, 2023 0

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. (ABBV) and ImmunoGen (IMGN) today announced …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

OKYO Pharma Limited: Another Ophthalmology Firm with Promising Eye Treatment

Vertex Pharmaceuticals Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Cognition Therapeutics CEO Issues Letter to Shareholders

CymaBay Therapeutics: New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

Yes, Compugen’s Stock is Soaring, But Why?

Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label

Why Arcturus Therapeutics Holdings’ Pipeline Products are Promising

Immunovent, Altimmune and Soleno: A Summary of Three Firms We Believe Have Promising Technologies and Treatments

Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

Merck & Invivyd in Today’s December 18, 2023 News

Prohost Letter #458 ~ Obesity

Editas Medicine and Vertex Pharmaceuticals: Non-Exclusive License Agreement in Cas9 Gene Editing Technology

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

AbbVie Inc to Acquire ImmunoGen